Patheon Acquires Roche API Site

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-12-07-2016, Volume 11, Issue 12

Patheon adds API manufacturing capacity with acquisition of Roche’s Florence, SC facility.

Patheon has signed an agreement to acquire an API manufacturing facility in Florence, SC, from Roche Holdings, Inc., which will provide Patheon with a major US API operation capable of supporting products from clinical scale to commercial manufacturing, according to a Nov. 28, 2016 press statement.

Patheon will acquire the 1,100-acre, 300,000 square-foot facility with manufacturing capacity for API ranging from development to manufacturing services. The acquisition expands the company’s capacity for manufacturing highly potent compounds and adds capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying, the company reports.

According to the announcement, Patheon will acquire the site for an immaterial sum, plus the cost of associated inventory and spare parts. The company also announced a multi-year supply arrangement with Roche, which Patheon expects will help defray the costs associated with running the site for the next few years while it adds new client work into the facility.


The site features reactors ranging from 50–11,000 liters producing multiple products simultaneously, and is compliant with applicable regulations, such as cGMP, safety, and environmental standards.

Soucre: Patheon